- Conditions
- Head Injury Trauma, Traumatic Brain Injury, Mild
- Interventions
- Clinical pathway 1: Guidelines plus biomarkers, Clinical guidelines only
- Diagnostic Test
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 6
- States / cities
- Sylmar, California • Torrance, California • Clinton Township, Michigan + 2 more
Location Directory
Clinical trials in Detroit, Michigan
This page shows live ClinicalTrials.gov search results for Detroit, Michigan, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
7245
Shown on this page
12
Current sort
Recently updated
Location scope
Detroit, MI
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 433–444 of 7,245 matching trials in Detroit, MI.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Acute Respiratory Failure
- Interventions
- IV Ganciclovir, Normal saline
- Drug
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 20
- States / cities
- Denver, Colorado • Baltimore, Maryland • Boston, Massachusetts + 16 more
- Conditions
- Hematopoietic Cell Transplantation Recipient, Leukemia, Solid Tumor
- Interventions
- Assessment of Therapy Complications, Questionnaire Administration
- Procedure · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Not listed
- Enrollment
- 25,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 163
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 124 more
- Conditions
- Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
- Interventions
- zolbetuximab, placebo, oxaliplatin, folinic acid, fluorouracil
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 565 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 51
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 42 more
- Conditions
- Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
- Interventions
- Opevesostat, Dexamethasone, Fludrocortisone acetate, Hydrocortisone, Abiraterone acetate, Prednisone acetate, Enzalutamide
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,314 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 63
- States / cities
- Tucson, Arizona • Irvine, California • Los Angeles, California + 56 more
- Conditions
- Transthyretin Amyloidosis With Cardiomyopathy
- Interventions
- Nucresiran, Sterile Normal Saline (0.9% NaCl)
- Drug
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 1,750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 45
- States / cities
- La Jolla, California • Laguna Hills, California • Stanford, California + 38 more
- Conditions
- Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction, Hypertension, Vascular Diseases, Cardiovascular Diseases, Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction
- Interventions
- Pulmonary Artery Denervation (PADN), Sham procedure control
- Device
- Lead sponsor
- Pulnovo Medical, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 14
- States / cities
- Tucson, Arizona • New Haven, Connecticut • Weston, Florida + 9 more
- Conditions
- Coronary Arterial Disease (CAD), de Novo Lesions in Native Coronary Arteries
- Interventions
- Drug Eluting Balloon, Drug eluting stent, Plain old balloon angioplasty
- Device · Procedure
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,616 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 48
- States / cities
- Scottsdale, Arizona • Jonesboro, Arkansas • La Jolla, California + 40 more
- Conditions
- Immunoglobulin G4 Related Disease
- Interventions
- Rilzabrutinib, Placebo, Glucocorticoid
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 21
- States / cities
- Fontana, California • Sacramento, California • San Jose, California + 18 more
- Conditions
- Locally Advanced Solid Tumor, Metastatic Solid Tumor
- Interventions
- NVL-330
- Drug
- Lead sponsor
- Nuvalent Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 17
- States / cities
- Irvine, California • Sacramento, California • Stanford, California + 13 more
- Conditions
- Lung Adenocarcinoma, Lung Adenocarcinoma, Mixed Subtype, Lung Large Cell Carcinoma, Lung Squamous Cell Carcinoma, Minimally Invasive Lung Adenocarcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7
- Interventions
- 3-Dimensional Conformal Radiation Therapy, Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Placebo Administration, Veliparib
- Radiation · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2026
- U.S. locations
- 232
- States / cities
- Anchorage, Alaska • Tucson, Arizona • Beverly Hills, California + 158 more
- Conditions
- Locally Advanced / Metastatic Solid Tumors
- Interventions
- CR-001, Paclitaxel, trifluridine and tipiracil, Pemetrexed, Carboplatin, Oxaliplatin, Gemcitabin, Cisplatin, Capecitabine, FOLFOX
- Drug
- Lead sponsor
- Crescent Biopharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 540 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 12 more